Protein biomarkers that can identify Alzheimer's have been discovered. With a simple blood test, even the earliest stages of Alzheimer’s and Mild Cognitive Impairment may be reliably differentiated from controls. Working in collaboration with dementia centers in the US and Europe, our vision is to combine early diagnosis of Alzheimer's with presently available therapies and future disease-modifying therapies.